<DOC>
	<DOCNO>NCT02578641</DOCNO>
	<brief_summary>This study multi-center , randomize , open label , Phase III clinical trial . Drugs use chemotherapy , gemcitabine carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving infusion person 's cytotoxic T lymphocytes ( CTL ) treat laboratory may help body build effective immune response kill tumor cell . Giving combination chemotherapy together laboratory-treated T lymphocyte may kill tumor cell . This Phase III trial ass combine gemcitabine-carboplatin ( GC ) follow adoptive T-cell therapy would improve clinical outcome patient advance nasopharyngeal carcinoma ( NPC ) . It also world 's first , large , Phase 3 T-cell therapy cancer trial ever conduct , enrollment ongoing 330 patient 29 hospital center across Asia United States . This clinical trial conduct back successful Phase 2 NPC trial involve 38 patient National Cancer Centre , Singapore . This trial produce best publish 2-year ( 62.9 % ) , median overall survival ( OS ) data ( 29.9 month ) 35 patient advanced NPC receive autologous EBV-specific CTL . Kindly see http : //www.ncbi.nlm.nih.gov/pmc/articles/PMC3978790/ Phase 2 publication title `` Adoptive T-cell Transfer Chemotherapy First line treatment Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma '' .</brief_summary>
	<brief_title>Multicentre , Randomized , Open-Label , Phase III Clinical Trial Advanced Nasopharyngeal Carcinoma Patients</brief_title>
	<detailed_description>330 patient randomize eligibility status fully determine informed consent obtain . Patients randomly allocate receive either Arm A ( Gemcitabine Carboplatin ( GC ) x 4 cycle EBV-specific CTL ) Arm B ( GC x 6 cycle alone ) 1:1 ratio use stratified block randomization scheme . The stratification variables country disease stage ( metastatic v locally recurrent ) After randomization , patient Arm A peripheral blood take establishment cytotoxic T cell line EBV transform lymphoblastoid cell line ( CTL ) . Within two week enrollment , patient commence combination GC chemotherapy total 4 cycle . Patients Stage 2 study receive EBV-specific CTL immunotherapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Key Inclusion Criteria 1 . Metastatic locally recurrent EBVpositive , nonkeratinizing and/ undifferentiated NPC* curative option chemoradiation surgery *Subjects enrol base confirmed histology diagnosis NPC 2 . Radiologically measurable disease 3 . Human Immunodeficiency Virus ( HIV ) negative* * Status HIV must confirm via HIV antibody test confirmatory test available within 12 month screen screen 4 . Bilirubin &lt; 2 x upper limit normal ( ULN ) aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &lt; 3 x ULN 5 . Calculated creatinine clearance ( CRCL ) ≥40 mL/min . Glomerular Filtration Rate ( GFR ) calculate base CockcroftGault method . 6 . Normal correct calcium level 7 . Absolute neutrophil count &gt; 1200/mm3 , hemoglobin ( Hb ) ≥10 g/dL platelet ≥100,000/mm3 8 . Male female 9 . Age ≥21 year 10 . Eastern Cooperative Oncology Group Performance Scale ( ECOGPS ) ≤2 11 . Written inform consent 12 . Life expectancy &gt; 6 month Key Exclusion Criteria 1 . Severe concomitant illness i.e . chronic obstructive pulmonary disease ( COPD ) , ischemic heart disease ( IHD ) , active congestive cardiac failure ( CCF ) , active angina pectoris , uncontrolled arrhythmia , uncontrolled hypertension 2 . HIV Positive* * Status HIV must confirm via HIV antibody test confirmatory test available within 12 month screen screen 3 . Pregnant lactating female 4 . Refuse use contraception trial ( male female patient ) 5 . Investigational therapy le one month prior study entry 6 . Preexisting peripheral neuropathy ( National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] ≥2 ) 7 . Central nervous system metastasis 8 . Previous concurrent cancer distinct primary site histology cancer evaluate study , EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis T1 ] cancer curatively treat &gt; 3 year prior study entry 9 . Positive hepatitis B surface antigen ( HBsAg ) result 10 . Known history hepatitis C recovery status determine time screen 11 . Prior chemotherapy metastatic locally recurrent disease Exceptions : Prior radiotherapy curative intent Prior chemoradiotherapy curative intent Adjuvant chemotherapy Localised palliative radiotherapy Prior chemotherapy must &gt; 6 month screen 12 ) Severe intercurrent infection 13 ) Prior immunotherapy metastatic locally recurrent disease Exception : • Adjuvant immunotherapy/ biologics</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>Epstein-Barr Virus</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Cytotoxic T Lymphocytes</keyword>
</DOC>